Form D · Pharmaceuticals
Gilgamesh Pharmaceuticals, Inc.
New York, NY · CIK 0001817048
Offering snapshot reported May 19, 2022 · SEC filing
- Reported sold
- $13.8M Offering amount: $50M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- May 16, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 19, 2022 | Initial | $13,761,009 | No comparison | 14 | SEC filing |
| Feb 18, 2022 | Initial | $0 | No comparison | 1 | SEC filing |
| May 6, 2021 | Initial | $34,701,837 | No comparison | Not reported | SEC filing |
| Sep 15, 2020 | Amendment | $735,000 | $610,000vs Aug 31, 2020 | 10 | SEC filing |
| Aug 31, 2020 | Initial | $125,000 | No comparison | 1 | SEC filing |
| Jul 22, 2020 | Initial | $150,000 | No comparison | 1 | SEC filing |
| Jul 10, 2020 | Initial | $2,434,845 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-446192
Shares of preferred stock of Issuer (Preferred Shares), and the shares of capital stock of the Issuer into which the Preferred Shares may convert.
Source: Form D, filed May 19, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Berman | Director |
| Gaetano Crupi | Director |
| Yoni Falkson | Executive |
| Laszlo Kiss | Executive |
| Andrew Kruegel | Director, Executive |
| Andrew Kruegel, Ph.D. | Executive |
| Amy Kruse | Director |
| Gerard Marek | Executive |
| Thomas Kevin Murphy | Executive |
| Thomas Kevin Murphy, Ph.D. | Executive |
| Dalibor Sames | Director |
| Phil Skolnick | Director |
| Jonathan Sporn | Director, Executive |
| Jonathan Sporn, M.D. | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
113 University Place Suite 1019
New York, NY, 10003
New York, NY, 10003